Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Acquired by Barclays PLC

Barclays PLC lifted its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 141.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 126,675 shares of the company's stock after purchasing an additional 74,130 shares during the period. Barclays PLC owned about 0.29% of Soleno Therapeutics worth $5,694,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Corebridge Financial Inc. increased its position in shares of Soleno Therapeutics by 2.9% in the 4th quarter. Corebridge Financial Inc. now owns 12,720 shares of the company's stock valued at $572,000 after purchasing an additional 357 shares during the last quarter. Summit Investment Advisors Inc. lifted its holdings in Soleno Therapeutics by 24.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 2,677 shares of the company's stock worth $120,000 after buying an additional 522 shares during the last quarter. AlphaQuest LLC boosted its position in shares of Soleno Therapeutics by 1,154.4% during the 4th quarter. AlphaQuest LLC now owns 715 shares of the company's stock worth $32,000 after acquiring an additional 658 shares in the last quarter. US Bancorp DE purchased a new position in shares of Soleno Therapeutics in the 4th quarter valued at about $34,000. Finally, Alliancebernstein L.P. raised its position in shares of Soleno Therapeutics by 3.5% during the 4th quarter. Alliancebernstein L.P. now owns 23,810 shares of the company's stock worth $1,070,000 after acquiring an additional 800 shares in the last quarter. Hedge funds and other institutional investors own 97.42% of the company's stock.

Soleno Therapeutics Trading Up 0.0 %

Shares of Soleno Therapeutics stock traded up $0.03 on Thursday, reaching $74.89. 146,406 shares of the stock were exchanged, compared to its average volume of 725,931. The firm has a market capitalization of $3.74 billion, a PE ratio of -22.64 and a beta of -2.29. The business has a fifty day moving average price of $59.07 and a two-hundred day moving average price of $53.31. Soleno Therapeutics, Inc. has a 1-year low of $36.93 and a 1-year high of $76.56.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.41). Research analysts expect that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SLNO. UBS Group set a $105.00 price target on shares of Soleno Therapeutics in a research note on Thursday, March 27th. Guggenheim reaffirmed a "buy" rating and issued a $81.00 target price (up from $70.00) on shares of Soleno Therapeutics in a research report on Friday, March 28th. Robert W. Baird boosted their price target on shares of Soleno Therapeutics from $72.00 to $102.00 and gave the company an "outperform" rating in a research report on Thursday, March 27th. Stifel Nicolaus lifted their target price on Soleno Therapeutics from $74.00 to $108.00 and gave the stock a "buy" rating in a research report on Friday, March 28th. Finally, Lifesci Capital raised shares of Soleno Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 4th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $104.67.

Insider Activity

In other Soleno Therapeutics news, insider Patricia C. Hirano sold 3,782 shares of the firm's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $70.11, for a total value of $265,156.02. Following the sale, the insider now directly owns 27,036 shares in the company, valued at approximately $1,895,493.96. This trade represents a 12.27 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Bhatnagar Anish sold 699,095 shares of the business's stock in a transaction dated Thursday, March 27th. The shares were sold at an average price of $67.62, for a total transaction of $47,272,803.90. Following the transaction, the chief executive officer now directly owns 577,076 shares of the company's stock, valued at $39,021,879.12. The trade was a 54.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 942,672 shares of company stock valued at $64,058,781. Company insiders own 12.30% of the company's stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.